Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients
In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to ...
